



News Release

October 15, 2015

MSD K.K.  
Kyorin Holdings, Inc.

**MSD Submits New Drug Application for Antiallergic Agent,  
Desloratadine to be Co-marketed with Kyorin**

MSD K.K. (Head office: Chiyoda-ku, Tokyo, President: Tony Alvarez, “MSD”) submitted today a new drug application for an antiallergic agent, desloratadine (generic name).

In November 2014, MSD, through its affiliate, signed a co-marketing agreement in Japan for desloratadine with Kyorin Pharmaceutical Co., Ltd. (Head office: Chiyoda-ku, Tokyo, President & CEO: Mitsutomo Miyashita, Ph.D., “Kyorin”), a wholly owned subsidiary of Kyorin Holdings, Inc. With the agreement, MSD and Kyorin will be co-marketing desloratadine after its approval and launch.

Desloratadine is a novel and second generation histamine H1-receptor antagonist. While it is under NDA review in Japan for the indications of allergic rhinitis, hives, and itching resulting from skin diseases (eczema/dermatitis, pruritus cutaneous), desloratadine has already had approved in more than 120 countries including the United States and Europe.

MSD is committed to the improvement of QOL of Japanese people by developing and delivering innovative medicines. This NDA submission reflects the company’s commitment demonstrated in the respiratory and allergic disease areas.

Kyorin aimed for, through the filing, increase of its lineup of products in its strategic areas of respiratory and ear-nose-throat diseases as well as enhancement of its presence in these areas.

###

Contact	
MSD K.K. Communications KITANOMARU SQUARE, 1-13-12, Kudan-Kita Chiyoda-ku, Tokyo 102-8667 Tel: 3-6272-1001 Fax: 3-6238-9136	Kyorin Holdings, Inc. President’s Office Corporate Communication 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo 101-8311 Tel: 3-3525-4707 Fax: 3-3525-4777